Sodium–glucose cotransporter inhibitors and oxidative stress

An update

Habib Yaribeygi, Stephen Atkin, Alexandra E. Butler, Amirhossein Sahebkar

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Sodium–glucose cotransporter 2 (SGLT2) inhibitors are therapeutic agents that have been used recently to reduce tubular absorption of glucose, leading to enhanced glycosuria, resulting in the reduction of blood glucose and improved diabetes control. Recent data suggest that SGLT2 inhibitors have antioxidant properties that may be key to the reduction in cardiovascular death found in clinical trials. Oxidative stress is involved in the development and progression of atherosclerosis, as well as underlying diabetes complications, and may result from either increased free-radical production, a reduction in antioxidative capacity, or a combination of both. In this report, we have reviewed the recent evidence of the impact that SGLT2 inhibition may have on improved oxidative stress by either amelioration of free-radical generation or potentiation of cellular antioxidative capacity, and its importance in the prevention of cardiovascular and diabetes complications.

Original languageEnglish
JournalJournal of Cellular Physiology
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Fingerprint

Oxidative stress
Diabetes Complications
Medical problems
Free Radicals
Oxidative Stress
Glycosuria
Blood Glucose
Atherosclerosis
Antioxidants
Clinical Trials
Glucose
Therapeutics

Keywords

  • diabetes
  • free radicals
  • glycosuria
  • oxidative stress
  • SGLT2 inhibitors

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Sodium–glucose cotransporter inhibitors and oxidative stress : An update. / Yaribeygi, Habib; Atkin, Stephen; Butler, Alexandra E.; Sahebkar, Amirhossein.

In: Journal of Cellular Physiology, 01.01.2018.

Research output: Contribution to journalArticle

@article{9981bb25f93847e3861148f06a298ff7,
title = "Sodium–glucose cotransporter inhibitors and oxidative stress: An update",
abstract = "Sodium–glucose cotransporter 2 (SGLT2) inhibitors are therapeutic agents that have been used recently to reduce tubular absorption of glucose, leading to enhanced glycosuria, resulting in the reduction of blood glucose and improved diabetes control. Recent data suggest that SGLT2 inhibitors have antioxidant properties that may be key to the reduction in cardiovascular death found in clinical trials. Oxidative stress is involved in the development and progression of atherosclerosis, as well as underlying diabetes complications, and may result from either increased free-radical production, a reduction in antioxidative capacity, or a combination of both. In this report, we have reviewed the recent evidence of the impact that SGLT2 inhibition may have on improved oxidative stress by either amelioration of free-radical generation or potentiation of cellular antioxidative capacity, and its importance in the prevention of cardiovascular and diabetes complications.",
keywords = "diabetes, free radicals, glycosuria, oxidative stress, SGLT2 inhibitors",
author = "Habib Yaribeygi and Stephen Atkin and Butler, {Alexandra E.} and Amirhossein Sahebkar",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/jcp.26760",
language = "English",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Sodium–glucose cotransporter inhibitors and oxidative stress

T2 - An update

AU - Yaribeygi, Habib

AU - Atkin, Stephen

AU - Butler, Alexandra E.

AU - Sahebkar, Amirhossein

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Sodium–glucose cotransporter 2 (SGLT2) inhibitors are therapeutic agents that have been used recently to reduce tubular absorption of glucose, leading to enhanced glycosuria, resulting in the reduction of blood glucose and improved diabetes control. Recent data suggest that SGLT2 inhibitors have antioxidant properties that may be key to the reduction in cardiovascular death found in clinical trials. Oxidative stress is involved in the development and progression of atherosclerosis, as well as underlying diabetes complications, and may result from either increased free-radical production, a reduction in antioxidative capacity, or a combination of both. In this report, we have reviewed the recent evidence of the impact that SGLT2 inhibition may have on improved oxidative stress by either amelioration of free-radical generation or potentiation of cellular antioxidative capacity, and its importance in the prevention of cardiovascular and diabetes complications.

AB - Sodium–glucose cotransporter 2 (SGLT2) inhibitors are therapeutic agents that have been used recently to reduce tubular absorption of glucose, leading to enhanced glycosuria, resulting in the reduction of blood glucose and improved diabetes control. Recent data suggest that SGLT2 inhibitors have antioxidant properties that may be key to the reduction in cardiovascular death found in clinical trials. Oxidative stress is involved in the development and progression of atherosclerosis, as well as underlying diabetes complications, and may result from either increased free-radical production, a reduction in antioxidative capacity, or a combination of both. In this report, we have reviewed the recent evidence of the impact that SGLT2 inhibition may have on improved oxidative stress by either amelioration of free-radical generation or potentiation of cellular antioxidative capacity, and its importance in the prevention of cardiovascular and diabetes complications.

KW - diabetes

KW - free radicals

KW - glycosuria

KW - oxidative stress

KW - SGLT2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85056651473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056651473&partnerID=8YFLogxK

U2 - 10.1002/jcp.26760

DO - 10.1002/jcp.26760

M3 - Article

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

ER -